New Class of Dizziness Medication Offers Hope for Vestibular Migraine Treatment

A new clinical trial suggests that a widely used class of drugs for vertigo and dizziness may also help reduce the frequency and severity of vestibular migraine, a condition affecting an estimated 1 to 3 percent of the global population. According to a study published June 20, 2026 in JAMA Neurology, patients treated with antihistamines—specifically meclizine and betahistine—experienced a 40 percent reduction in migraine attacks over 12 weeks compared to a placebo group. The findings, led by researchers at the University of California, San Francisco, mark the first time this drug class has shown efficacy in randomized controlled trials for vestibular migraine, a subtype of migraine that causes balance disorders.

The study enrolled 217 adults diagnosed with vestibular migraine, a condition characterized by recurrent headaches accompanied by vertigo, dizziness, or imbalance. Participants received either meclizine (12.5 mg twice daily), betahistine (16 mg three times daily), or a placebo. By the trial’s end, 62 percent of patients on meclizine and 58 percent on betahistine reported at least a 50 percent reduction in migraine episodes, compared to 30 percent in the placebo group. “These results are particularly promising because antihistamines are already FDA-approved for dizziness and are widely prescribed,” said Dr. Emily Carter, lead author and a neurologist at UCSF. “If confirmed in larger trials, this could offer a safe, low-cost treatment option for millions of patients.”

Vestibular migraine is often misdiagnosed or underdiagnosed, partly because its symptoms overlap with other balance disorders like Ménière’s disease or benign paroxysmal positional vertigo. The American Migraine Foundation estimates that up to 10 percent of migraine sufferers experience vestibular symptoms, yet fewer than 20 percent receive specialized treatment. Current guidelines from the American Headache Society recommend preventive therapies such as beta-blockers or calcium channel blockers, but these carry side effects like fatigue or blood pressure changes. Antihistamines, by contrast, have a well-established safety profile for long-term use.

The new findings build on observational data from 2024, when a retrospective analysis in Cephalalgia found that patients prescribed meclizine for vertigo reported fewer migraine attacks than those on other treatments. However, that study lacked a control group, leaving open the question of whether the improvement stemmed from the drug or other factors. The UCSF trial addresses that gap with its placebo-controlled design, though it was limited to a 12-week period—too short to assess long-term safety or efficacy. “We need longer studies to confirm durability and rule out rebound effects,” noted Dr. Carter.

Not all experts are convinced the results are ready for clinical use. Dr. Rajesh Patel, a headache specialist at Mayo Clinic, cautioned that the trial’s response rates—while statistically significant—were modest. “A 40 percent reduction is meaningful, but we’d want to see 60 to 70 percent before recommending this as first-line therapy,” he said. Patel also pointed out that the study excluded patients with severe cardiovascular conditions, where antihistamines could interact with other medications. The UCSF team acknowledged these limitations but argued that the drug’s existing safety profile makes it a viable candidate for further investigation.

If replicated, the findings could reshape treatment paradigms for vestibular migraine, a condition that currently lacks FDA-approved preventive therapies. The National Institute of Neurological Disorders and Stroke estimates that direct and indirect costs of migraine in the U.S. exceed $78 billion annually, with vestibular migraine contributing disproportionately to disability. “Access to effective, low-cost treatments could significantly reduce healthcare burdens,” said Dr. Carter. “But we must emphasize that these results are preliminary—patients should not self-medicate based on this single study.”

The next phase of research will involve larger, multicenter trials to validate the UCSF findings and explore optimal dosing. The team is also collaborating with the Vestibular Disorders Association to raise awareness about vestibular migraine and improve diagnostic accuracy. In the meantime, the American Migraine Foundation advises patients experiencing vestibular symptoms to consult a neurologist specializing in headache disorders, as accurate diagnosis remains the first step toward effective management.

The study was funded by the National Institutes of Health and supported in part by the Migraine Research Foundation. Full results are available in the JAMA Neurology paper, titled “Efficacy of Antihistamines in Vestibular Migraine: A Randomized Controlled Trial.”